Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LONITEN vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
FDA-approved for treatment of hypertension (as a third-line agent in patients who have not responded to other antihypertensives),Off-label: treatment of androgenetic alopecia (topical formulation; oral low-dose minoxidil is also used for hair loss)
Hypertension
10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life: 4.2 hours (range 3.5–5.5); clinically, half-life extends to 14–23 hours after chronic dosing due to drug accumulation.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Primarily metabolized by the liver via glucuronidation (UGT1A1) to inactive metabolites; less than 20% excreted unchanged in urine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 85% (12% unchanged, 73% as glucuronide conjugates); biliary/fecal: 3%
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
No significant plasma protein binding (<1%); binds to vasular smooth muscle tissue.
~90%, primarily to albumin
1.5 L/kg (range 1.2–2.0); large Vd indicates extensive tissue binding, primarily to arteriolar smooth muscle.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 95% (rapidly and completely absorbed).
Oral: 50–60% (extensive first-pass metabolism)
No dose adjustment needed for mild to moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), reduce dose by 50% and monitor closely.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment as drug may accumulate. Reduce initial dose by 50% in Child-Pugh class C.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
For hypertension: 0.1-0.2 mg/kg orally once daily, titrate to max 0.5 mg/kg/day divided every 12-24 hours, max 50 mg/day.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at lower end of dosing range (2.5-5 mg twice daily) due to increased sensitivity; titrate slowly. Monitor for orthostatic hypotension and renal function.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Must be administered under close medical supervision; may cause pericardial effusion, occasionally progressing to cardiac tamponade, especially in patients with renal impairment or those on dialysis.
None
Monitor for pericardial effusion and tamponade; discontinue if effusion occurs and treat appropriately.,May cause severe fluid retention and congestive heart failure; administer with a diuretic.,Can exacerbate angina; use with caution in patients with coronary artery disease.,Hypertrichosis (excessive hair growth) is common; reversible upon discontinuation.,Monitor blood pressure closely; avoid abrupt withdrawal to prevent rebound hypertension.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to minoxidil or any component of the formulation.,Pheochromocytoma (due to risk of catecholamine release).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-sodium foods and excessive alcohol intake, which can exacerbate fluid retention and hypertension. No specific food interactions with minoxidil itself, but maintain a balanced diet as part of hypertension management.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Pregnancy Category C. Fetal risks: First trimester - limited human data; animal studies show fetal resorptions and cardiovascular anomalies at high doses. Second/third trimesters - possible fetal hypotension, oligohydramnios, and hypertrichosis. Use only if benefit outweighs risk.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Excreted in breast milk; M/P ratio unknown. Avoid use while breastfeeding due to potential adverse effects (e.g., hypotension) in the infant.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy may require titration based on maternal response and tolerability.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Initiate at low doses (2.5 mg BID) and titrate slowly to avoid severe hypotension. Monitor for pericardial effusion, especially in patients with renal impairment. Use with a diuretic and beta-blocker to prevent reflex tachycardia and fluid retention. Abrupt discontinuation can cause rebound hypertension.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly.,Report unusual weight gain, swelling in ankles or legs, shortness of breath, or chest pain.,You may notice increased hair growth on face, arms, or back; this is reversible after stopping.,Avoid alcohol and excessive salt intake to help control blood pressure.,Use sunscreen and protective clothing as you may become more sensitive to sunlight.,Do not take over-the-counter medications without checking with your doctor.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LONITEN vs ALDORIL 15, answered by our medical review team.
LONITEN is a Antihypertensive that works by Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LONITEN and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LONITEN is: 10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LONITEN and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LONITEN is classified as Category C. Pregnancy Category C. Fetal risks: First trimester - limited human data; animal studies show fetal resorptions and cardiovascular anomalies at high doses. Second/third trimesters -. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.